“When you think about Copaxone, many people try to equate it to Lovenox. It is much, much different—vastly more complex—than Lovenox will ever be. We have not characterized it. We don't believe it can be fully characterized."
Maybe indeed Teva's capability of full characterization isn't that great.
Market Data 
Markets 
AI
